Table 7.
Pairwise heterogeneity assessment for core analyses
| Outcome | Treatments compared | Number of trials | I 2 | I 2 confidence interval | Q-statistic |
Q
p value |
|---|---|---|---|---|---|---|
| ADHD-RS-IV | PBO, GXR | 5 | 0.00 | (0.00, 0.51) | 1.68 | 0.79 |
| PBO, LDX | 3 | 0.94 | (0.86, 0.98) | 34.39 | <0.01 | |
| PBO, ATX | 11 | 0.17 | (0.00, 0.57) | 12.01 | 0.28 | |
| PBO, MPH-ER | 2 | 0.57 | – | 2.32 | 0.13 | |
| ATX, MPH-ER | 2 | 0.32 | – | 1.48 | 0.22 | |
| CGI-I | PBO, GXR | 5 | 0.36 | (0.00, 0.76) | 6.22 | 0.18 |
| PBO, LDX | 2 | 0.94 | – | 16.86 | <0.01 | |
| PBO, ATX | 2 | 0.86 | – | 7.07 | 0.01 | |
| PBO, MPH-ER | 3 | 0.39 | (0.00, 0.81) | 3.27 | 0.20 | |
| PBO, MPH-IR | 2 | 0.00 | – | 0.27 | 0.60 | |
| MPH-ER, MPH-IR | 3 | 0.41 | (0.00, 0.82) | 3.38 | 0.18 |
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale Version IV, ATX atomoxetine, GXR guanfacine extended release, LDX lisdexamfetamine dimesylate, MPH-ER methylphenidate extended release, MPH-IR methylphenidate immediate release, PBO placebo